SCM
SNDX icon

Silverarc Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Silverarc Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.5M Buy
1,214,390
+325,403
+37% +$6.77M 2.76% 10
2026
Q1 		$20.8M Buy
888,987
+246,088
+38% +$5.35M 2.12% 17
2025
Q4 		$13.5M Buy
642,899
+179,191
+39% +$3.13M 1.88% 17
2025
Q3 		$7.13M Buy
463,708
+60,744
+15% +$795K 0.96% 32
2025
Q2 		$3.77M Sell
402,964
-906,260
-69% -$9.97M 0.7% 34
2025
Q1 		$16.1M Buy
1,309,224
+78,824
+6% +$1.11M 3.29% 9
2024
Q4 		$16.3M Buy
1,230,400
+851,654
+225% +$14.6M 3.56% 9
2024
Q3 		$7.29M Buy
378,746
+8,746
+2% +$181K 1.64% 18
2024
Q2 		$7.6M Buy
+370,000
New +$7.74M 1.79% 18
2023
Q4 		– Sell
-20,000
Closed -$290K – 86
2023
Q3 		$290K Hold
20,000
– – 0.09% 73
2023
Q2 		$419K Buy
+20,000
New +$416K 0.13% 69
2022
Q3 		– Sell
-107,852
Closed -$2.08M – 90
2022
Q2 		$2.08M Buy
107,852
+6,405
+6% +$107K 0.64% 40
2022
Q1 		$1.76M Buy
101,447
+1,447
+1% +$24.4K 0.73% 33
2021
Q4 		$2.19M Buy
+100,000
New +$1.85M 0.89% 37
2021
Q3 		– Sell
-34,727
Closed -$596K – 105
2021
Q2 		$596K Buy
34,727
+14,727
+74% +$270K 0.27% 76
2021
Q1 		$447K Sell
20,000
-10,000
-33% -$226K 0.24% 75
2020
Q4 		$667K Buy
+30,000
New +$622K 0.39% 63

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Silverarc Capital Management's SNDX Position: Q2 2026 in Review

Silverarc Capital Management increased its Syndax Pharmaceuticals (SNDX) stake by 37% in Q2 2026, buying an estimated $6.77M and bringing the position to 1,214,390 shares worth $26.5M. The position accounts for 2.76% of the portfolio, ranked #10.

Silverarc Capital Management first reported a position in SNDX in Q4 2020 and has held it in 17 quarters since. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Silverarc Capital Management held 1,214,390 shares of Syndax Pharmaceuticals worth $26.5M as of Q2 2026.
  • Silverarc Capital Management bought 325,403 Syndax Pharmaceuticals shares in Q2 2026, an estimated $6.77M.
  • Syndax Pharmaceuticals made up 2.76% of Silverarc Capital Management's portfolio in Q2 2026, its #10 holding.
  • Silverarc Capital Management first reported a position in Syndax Pharmaceuticals in Q4 2020 and has held it in 17 quarters since.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.